Printer Friendly

Celgene drops option on OncoMed's navicixizumab.

M2 PHARMA-September 20, 2018-Celgene drops option on OncoMed's navicixizumab

(C)2018 M2 COMMUNICATIONS

Celgene Corp (NASDAQ:CELG) has decided not to exercise its option to license the bispecific antibody navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83) from OncoMed Pharmaceuticals Inc (NASDAQ: OMED), OncoMed revealed on Thursday.

The decision was said to be based on strategic product portfolio considerations.

Celgene still retains its options to license OncoMed's etigilimab (anti-TIGIT monoclonal antibody, OMP-313M32) and rosmantuzumab (anti-RSPO3, OMP-131R10).

OncoMed is currently conducting a Phase 1b clinical trial of navicixizumab in combination with paclitaxel in patients with platinum-resistant late-stage ovarian cancer. Interim data will be presented at next month's European Society of Medical Oncology meeting in Munich.

"With the global development and commercialisation of navicixizumab remaining under our control, we are evaluating potential opportunities for the program and will continue to assess the data as it evolves for navicixizumab in combination with paclitaxel in heavily pretreated platinum-resistant ovarian cancer patients," said OncoMed's president and CEO, Dr John Lewicki.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Sep 20, 2018
Words:173
Previous Article:ProAxsis assays selected for 1,000-patient respiratory trial.
Next Article:Study identifies existing drug which could protect against Alzheimer's memory-loss.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters